Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gemtuzumab ozogamicin

View Patient Information
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody
hP67.6-Calicheamicin
US brand name:Mylotarg
Code name:CDP-771
CMA-676
WAY-CMA-676
NSC code:720568
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search